Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)’s share price rose 4% during trading on Monday . The stock traded as high as $9.24 and last traded at $9.20, with a volume of 858,876 shares changing hands. The stock had previously closed at $8.85.

ACHN has been the topic of several recent analyst reports. Chardan Capital initiated coverage on shares of Achillion Pharmaceuticals in a report on Thursday, July 14th. They issued a “sell” rating and a $4.00 target price on the stock. Robert W. Baird reissued an “outperform” rating and issued a $10.00 target price on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 27th. Leerink Swann reissued a “hold” rating and issued a $9.00 target price on shares of Achillion Pharmaceuticals in a report on Wednesday, May 25th. Finally, JMP Securities raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a report on Thursday, July 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.63.

The firm’s 50 day moving average price is $8.68 and its 200-day moving average price is $8.13. The company has a market cap of $1.26 billion and a P/E ratio of 188.78.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the company earned ($0.25) EPS. Analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.63) earnings per share for the current year.

A hedge fund recently raised its stake in Achillion Pharmaceuticals stock. Rhumbline Advisers raised its stake in shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 14.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 117,525 shares of the biopharmaceutical company’s stock after buying an additional 14,425 shares during the period. Rhumbline Advisers owned approximately 0.09% of Achillion Pharmaceuticals worth $1,268,000 at the end of the most recent reporting period.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.